Header Logo

Connection

JOSEPH JANKOVIC to alpha-Synuclein

Back to Details
This is a "connection" page, showing publications JOSEPH JANKOVIC has written about alpha-Synuclein.
JOSEPH JANKOVIC
Connection Strength
4.386
alpha-Synuclein
  1. Slowing Parkinson's Disease Progression with Vaccination and Other Immunotherapies. CNS Drugs. 2022 04; 36(4):327-343.
    View in: PubMed
    Score: 0.706
  2. Targeting a-Synuclein in Parkinson's Disease: Progress Towards the Development of Disease-Modifying Therapeutics. Drugs. 2019 Jun; 79(8):797-810.
    View in: PubMed
    Score: 0.584
  3. Pathogenesis-targeted therapeutic strategies in Parkinson's disease. Mov Disord. 2019 01; 34(1):41-44.
    View in: PubMed
    Score: 0.564
  4. Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti-a-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease: A Randomized Clinical Trial. JAMA Neurol. 2018 10 01; 75(10):1206-1214.
    View in: PubMed
    Score: 0.557
  5. Immunologic treatment of Parkinson's disease. Immunotherapy. 2018 02; 10(2):81-84.
    View in: PubMed
    Score: 0.532
  6. The role of alpha-synuclein in melanin synthesis in melanoma and dopaminergic neuronal cells. PLoS One. 2012; 7(9):e45183.
    View in: PubMed
    Score: 0.367
  7. Gene dosage analysis of alpha-synuclein (SNCA) in patients with Parkinson's disease. Mov Disord. 2006 May; 21(5):728-9.
    View in: PubMed
    Score: 0.236
  8. Genetic modifiers of risk and age at onset in GBA associated Parkinson's disease and Lewy body dementia. Brain. 2020 01 01; 143(1):234-248.
    View in: PubMed
    Score: 0.152
  9. Juvenile parkinsonism: Differential diagnosis, genetics, and treatment. Parkinsonism Relat Disord. 2019 10; 67:74-89.
    View in: PubMed
    Score: 0.147
  10. Parkinson's disease age at onset genome-wide association study: Defining heritability, genetic loci, and a-synuclein mechanisms. Mov Disord. 2019 06; 34(6):866-875.
    View in: PubMed
    Score: 0.144
  11. Head injury, a-synuclein Rep1, and Parkinson's disease. Ann Neurol. 2012 Jan; 71(1):40-8.
    View in: PubMed
    Score: 0.087
  12. Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson's disease. Neurosci Lett. 2010 Aug 09; 480(1):78-82.
    View in: PubMed
    Score: 0.078
  13. DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain. 2010 Mar; 133(Pt 3):713-26.
    View in: PubMed
    Score: 0.077
  14. The role of autophagy-lysosome pathway in neurodegeneration associated with Parkinson's disease. Brain. 2008 Aug; 131(Pt 8):1969-78.
    View in: PubMed
    Score: 0.066
  15. Resveratrol-activated AMPK/SIRT1/autophagy in cellular models of Parkinson's disease. Neurosignals. 2011; 19(3):163-74.
    View in: PubMed
    Score: 0.021
  16. Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol. 2011 Mar; 69(3):570-80.
    View in: PubMed
    Score: 0.021
  17. Nurr1 in Parkinson's disease and related disorders. J Comp Neurol. 2006 Jan 20; 494(3):495-514.
    View in: PubMed
    Score: 0.014
  18. Nitric oxide mediates increased susceptibility to dopaminergic damage in Nurr1 heterozygous mice. FASEB J. 2005 Sep; 19(11):1441-50.
    View in: PubMed
    Score: 0.014
  19. The alpha-synuclein gene is not a major risk factor in familial Parkinson disease. Neurogenetics. 1999 Sep; 2(3):191-2.
    View in: PubMed
    Score: 0.009
  20. The G209A mutation in the alpha-synuclein gene is not detected in familial cases of Parkinson disease in non-Greek and/or Italian populations. Arch Neurol. 1998 Dec; 55(12):1521-3.
    View in: PubMed
    Score: 0.009
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.